Vitamin D Receptor Gene Polymorphisms and Breast Cancer Risk in Kazakhstan

Ainur Akilzhanova¹, Zhannur Abilova¹, Nurgul Sikhayeva², Ivan Shtefanov³, Abay Makishev³, Tasbolat Adylkhanov⁴, Tolebay Rakhypbekov⁴, Zhaxybay Zhumadilov¹, Kuvat Momynaliev²

¹Center for Life Sciences, Nazarbayev University, Astana, Kazakhstan; ²National Center for Biotechnology, Almaty, Kazakhstan; ³Astana Medical University, Astana, Kazakhstan; ⁴Semey State Medical University, Semey, Kazakhstan

Vol. 2, Suppl. (2013) | ISSN 2166-7403 (online) DOI 10.5195/cajgh.2013.95 | http://cajgh.pitt.edu

(cc) BY

New articles in this journal are licensed under a Creative Commons Attribution 3.0 United States License.



This journal is published by the <u>University Library System</u> of the <u>University of Pittsburgh</u> as part of its <u>D-Scribe Digital Publishing Program</u> and is cosponsored by the <u>University of Pittsburgh Press</u>.

Abstract

Introduction: The steroid hormone 1,25-dihydroxyvitamin D3 is thought to protect against breast cancer. The activity of 1,25-dihydroxyvitamin D3 is mediated via the vitamin D receptor (VDR), and a number of polymorphisms in the *VDR* gene have been identified. These result in distinct genotypes, some of which may alter susceptibility to breast cancer. Two common single nucleotide polymorphisms (SNP) in the *VDR* gene (*VDR*), rs1544410 (BsmI) and rs2228570 (FokI), have been inconsistently associated with breast cancer risk. Increased risk has been reported for the FokI ff genotype, which encodes a less transcriptionally active isoform of *VDR*. A reduced risk has been reported for the BsmI BB genotype which may influence VDR mRNA stability.

Aim: We have investigated whether specific VDR gene polymorphisms are associated with breast cancer risk in Kazakhstan women.

Material and Methods: In a case–control study, female breast cancer patients (315) and a female control group (n=604) were tested for two VDR polymorphisms. Statistical analysis was conducted using SPSS19.0.

Results: The *VDR* rs2228570 (FokI) polymorphism was associated with an increased occurrence of BC [rs2228570 (folk) ff vs. FF genotype: OR=1.71; 95% CI=1.21-2.43]. No association was noted between rs1544410 (BsmI) BB and breast cancer risk [OR=0.68; 95% CI=0.49-0.95].

Conclusion: Although the factors that increase breast cancer susceptibility remain uncertain, future large studies should integrate genetic variation in VDR with biomarkers of vitamin D status. Additional testing on the effect of varying genotypes on the functional mechanisms of the *VDR* could help to improve future testing and treatment of woman at risk for breast cancer.

Keywords: breast cancer, gene polymorphysm, vitamin D receptors, genetype suseptibility

This work is licensed under a Creative Commons Attribution 3.0 United States License.

This journal is published by the <u>University Library System</u> of the <u>University of Pittsburgh</u> as part of its <u>D-Scribe Digital Publishing Program</u> and is cosponsored by the <u>University of Pittsburgh Press</u>.

